Hainan Simcere Pharmaceutical Co. Ltd. has disclosed kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Rpxds Co. Ltd. has described α-ketoglutarate-dependent dioxygenase FTO inhibitors reported to be useful for the treatment of obesity, diabetes, atherosclerosis and more.

Sporos Biodiscovery Inc. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.

Viking Therapeutics Inc. has identified amylin analogues acting as calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of diabetes and obesity.

ST Pharm Co. Ltd. has synthesized pyrrolopyridine compounds reported to be useful for the treatment of HIV infections.

Rezolute Inc. has disclosed plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of diabetic macular edema and uveitis.

CSPC Megalith Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising anti-tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of pancreatic and breast cancer.

Takeda Pharmaceutical Co. Ltd. has divulged polypeptides acting as gastric inhibitory polypeptide receptor (GIPR) agonists reported to be useful for the treatment of nausea and vomiting.

Lifemine Therapeutics Inc. has identified serine/threonine-protein phosphatase 2B (PPP3CC; PP2Bγ; calcineurin) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome (SARS), fungal infections, transplant rejection, and dermatological, respiratory and eye disorders.

Maplight Therapeutics Inc. has synthesized G protein-coupled receptor GPR6 inverse agonists reported to be useful for the treatment of anxiety, bipolar disorder, eating disorders, depression, schizophrenia, Huntington’s disease, Parkinson’s disease and Alzheimer’s disease, among others.